Noopept
Noopept is a peptide, indexed here under Neuroactive peptides.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Neuroactive peptides |
| CAS registry number | 157115-85-0[1] |
| PubChem CID | 180496[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C17H22N2O4[1] |
| Molecular weight | 318.4 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Noopept, reported in the literature as GVS-111 and by the generic name omberacetam, is described in a 2007 Journal of Psychopharmacology paper as a proline-containing dipeptide and in 1997 papers in General Pharmacology and the European Journal of Drug Metabolism and Pharmacokinetics as a dipeptide analogue of piracetam, the latter reporting that its major metabolite in rat brain resembles an endogenous neuropeptide. It is a dipeptide ethyl ester rather than a free peptide.
The retrieved records are cell-culture and rodent neuroprotection work. A 2000 Bulletin of Experimental Biology and Medicine paper reports in vitro oxygen-glucose deprivation and glutamate toxicity models, a 2003 International Journal of Developmental Neuroscience paper reports oxidative damage and apoptosis endpoints in cultured human cortical neurons, a 1999 Behavioural Pharmacology paper reports a photochemical stroke model, a 2008 Bulletin of Experimental Biology and Medicine paper reports NGF and BDNF expression in rat hippocampus, a 2011 Journal of Molecular Biology paper reports alpha-synuclein amyloid cytotoxicity, a 2014 Journal of Biomedical Science paper reports an Alzheimer-related cellular model, a 2014 paper reports incretin system parameters in rats with experimental diabetes, and a 2021 Molecular Neurobiology paper reports neuropathic pain and hippocampal endpoints in diabetic rats.
[3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]Reported mechanism
A proline-containing dipeptide; the retrieved records report effects on voltage-gated calcium and potassium channels, NGF and BDNF expression, and TRPV1-related signalling in rodent models.
[4, 9, 13]Stated in the titles of the cited 1997 General Pharmacology, 2008 Bulletin of Experimental Biology and Medicine and 2021 Molecular Neurobiology papers.
Targets named in the cited records: NGF and BDNF expression, voltage-gated ion channels, TRPV1.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Noopept appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- omberacetam
- GVS-111
- N-phenylacetyl-L-prolylglycine ethyl ester
Where this page sits
Research records
Cited research records for Noopept, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Compounds indexed next to it
Class page: Neuroactive peptides. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Noopept?
Noopept, reported in the literature as GVS-111 and by the generic name omberacetam, is described in a 2007 Journal of Psychopharmacology paper as a proline-containing dipeptide and in 1997 papers in General Pharmacology and the European Journal of Drug Metabolism and Pharmacokinetics as a dipeptide analogue of piracetam, the latter reporting that its major metabolite in rat brain resembles an endogenous neuropeptide. It is a dipeptide ethyl ester rather than a free peptide.
Which class is Noopept indexed under?
Noopept is indexed under Neuroactive peptides. The compounds grouped here are peptides whose retrieved literature examines effects in the nervous system.
What does the FDA application register show for Noopept?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.
Sources
- PubChem Compound Summary for CID 180496, 1-(2-Phenylacetyl)-L-prolylglycine ethy ester. PubChem, National Library of Medicine (2026). pubchem:180496
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:noopept
- The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model. Journal of psychopharmacology (Oxford, England) (2007). pmid:17092975
- The effects of piracetam and its novel peptide analogue GVS-111 on neuronal voltage-gated calcium and potassium channels. General pharmacology (1997). pmid:9195198
- The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycine. European journal of drug metabolism and pharmacokinetics (1997). pmid:9358206
- Neuroprotective properties of nootropic dipeptide GVS-111 in in vitro oxygen-glucose deprivation, glutamate toxicity and oxidative stress. Bulletin of experimental biology and medicine (2000). pmid:11177296
- GVS-111 prevents oxidative damage and apoptosis in normal and Down's syndrome human cortical neurons. International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience (2003). pmid:12711349
- Memory restoring and neuroprotective effects of the proline-containing dipeptide, GVS-111, in a photochemical stroke model. Behavioural pharmacology (1999). pmid:10780261
- Noopept stimulates the expression of NGF and BDNF in rat hippocampus. Bulletin of experimental biology and medicine (2008). pmid:19240853
- Neuroprotective and nootropic drug noopept rescues α-synuclein amyloid cytotoxicity. Journal of molecular biology (2011). pmid:21986202
- Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation. Journal of biomedical science (2014). pmid:25096780
- Noopept normalizes parameters of the incretin system in rats with experimental diabetes. Bulletin of experimental biology and medicine (2014). pmid:25065315
- Noopept Attenuates Diabetes-Mediated Neuropathic Pain and Oxidative Hippocampal Neurotoxicity via Inhibition of TRPV1 Channel in Rats. Molecular neurobiology (2021). pmid:34241806
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.